Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
不适用
已完成
NCT03077360
| 适应症 | Diabetes Mellitus, Type 2, Pre-diabetes, Obesity |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | University of Colorado, Denver |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 62 人 |
|---|
| 干预(药物) | Lifestyle |
|---|
| 开始日期 | 2017年2月1日 |
|---|
| 完成日期 | 2020年11月19日 |
|---|
| 结果公布日 | 2022年6月21日 |
|---|
摘要
The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for type 2 diabetes. To attain the overall objective, the investigators propose three specific aims: 1. Identify the influence of sarcolemmal DAG and sphingolipids on cell signaling and insulin sensitivity before and after insulin sensitizing lifestyle interventions. Strong preliminary data shape the hypothesis that sarcolemmal 1,2-disaturated DAG and C18:0 ceramide species will decrease after insulin sensitizing lifestyle interventions, leading to less Protein kinase C (PKC) and Protein phosphatase 2A (PP2A) activation, and enhanced insulin signaling. Skeletal muscle DAG and sphingolipid isomers, species, localization, and de novo synthesis will be measured before and after diet-induced weight loss or exercise training interventions in obese men and women. Insulin sensitivity will be measured using insulin clamps, and muscle lipids using Liquid Chromatography Mass Spectrometry (LC/MS). 2. Determine the impact of mitochondrial/ER (endoplasmic reticulum) DAG and
Percent Change in Insulin Sensitivity Compared to Baseline Measurement.
Baseline and 12 weeks · Percent change
| Weight Loss Only | 31.8 ± 8.8 Percent change |
|---|
| Exercise Only | 17.4 ± 8.7 Percent change |
|---|
| Delayed Intervention Control | -4.8 ± 9.3 Percent change |
|---|
Percent Change in Localized Muscle Lipids Compared to Baseline
Baseline and 12 weeks · percentage change
| Weight Loss Only | -25 ± 6 percentage change |
|---|
| Exercise Only | -30 ± 7 percentage change |
|---|
| Delayed Intervention Control | 5 ± 6 percentage change |
|---|
| Weight Loss Only | -20 ± 5 percentage change |
|---|
| Exercise Only | -25 ± 5 percentage change |
|---|
| Delayed Intervention Control | 10 ± 3 percentage change |
|---|
Percent Change in Body Weight Compared to Baseline Measurement
Baseline, 3 Months · Percent Change
| Weight Loss Only | -10.5 ± 0.9 Percent Change |
|---|
| Exercise Only | -0.5 ± 0.5 Percent Change |
|---|
| Delayed Intervention Control | 0.5 ± 0.4 Percent Change |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。